💨 Abstract
The World Health Organization (WHO) has prequalified Bavarian Nordic's mpox vaccine for adolescents aged 12-17, following EU approval. The decision aims to protect a vulnerable age group concerned by the global outbreak of mpox, a viral infection causing flu-like symptoms and skin lesions. Bavarian Nordic plans a clinical trial to assess the vaccine's safety in children aged 2-12.
Courtesy: theprint.in
Summarized by Einstein Beta 🤖
Suggested
'Progressive parties' to hold convention in Nashik to discuss strategies for assembly polls
Second phase of polio vaccination campaign begins in Gaza, WHO says
Dollar holds near highs as investors parse China's stimulus plans; euro dips
"Preposterous imputations":India hits back after Canada cites Indian diplomats as 'persons of interest'
Soccer-Romangoli steps down as San Lorenzo head coach
Cricket-England captain Stokes returns for second Pakistan test
Google wants US judge's app store ruling put on hold
"Did not take any tips from Ajay": Kajol calls herself "asli singham" as she essays cop avatar in 'Do Patti'
Real estate sector records highest-ever equity investment since 2018: CBRE
Soccer-FIFA to open dialogue on transfer rules after EU verdict
Powered by MessengerX.io